Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down Following Insider Selling

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) gapped down before the market opened on Thursday following insider selling activity. The stock had previously closed at $35.05, but opened at $33.94. Y-mAbs Therapeutics shares last traded at $34.84, with a volume of 1,901 shares changing hands.

Specifically, Director Johan Wedell-Wedellsborg sold 25,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, May 28th. The shares were sold at an average price of $36.34, for a total value of $908,500.00. Following the transaction, the director now owns 4,453,465 shares in the company, valued at $161,838,918.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Tuesday, July 20th. The stock was sold at an average price of $32.47, for a total transaction of $129,880.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 290,471 shares of company stock worth $10,171,239. 38.40% of the stock is currently owned by company insiders.

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $68.00 price target on shares of Y-mAbs Therapeutics in a research report on Wednesday, July 7th. Wedbush lowered their price objective on shares of Y-mAbs Therapeutics from $67.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 21st. Zacks Investment Research cut shares of Y-mAbs Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 13th. Finally, Bank of America upgraded shares of Y-mAbs Therapeutics from a “neutral” rating to a “buy” rating in a research report on Friday, May 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $54.13.

The firm’s 50 day simple moving average is $34.42.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Thursday, May 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.14. The company had revenue of $5.38 million for the quarter, compared to analyst estimates of $35.67 million. On average, analysts anticipate that Y-mAbs Therapeutics, Inc. will post -1.29 EPS for the current year.

Large investors have recently modified their holdings of the business. Penserra Capital Management LLC lifted its stake in shares of Y-mAbs Therapeutics by 171.9% in the 4th quarter. Penserra Capital Management LLC now owns 930 shares of the company’s stock valued at $46,000 after purchasing an additional 588 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at $46,000. Pacer Advisors Inc. lifted its stake in shares of Y-mAbs Therapeutics by 137.2% in the 1st quarter. Pacer Advisors Inc. now owns 1,812 shares of the company’s stock valued at $55,000 after purchasing an additional 1,048 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at $89,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at $97,000. 60.77% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Further Reading: What is the definition of a trade war?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.